董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Gregory H. Bailey | 男 | Director | 69 | 3.00万美元 | 未持股 | 2025-07-25 |
| Steven Mintz | 男 | Director | 59 | 14.32万美元 | 未持股 | 2025-07-25 |
| Jean Christophe Renondin | 男 | Director | 64 | 12.70万美元 | 未持股 | 2025-07-25 |
| James Mellon | 男 | Director | 68 | 3.00万美元 | 未持股 | 2025-07-25 |
| Justin Stebbing | 男 | Director and Chairman of the Board | 54 | 15.12万美元 | 未持股 | 2025-07-25 |
| Gregory H. Bailey | 女 | Director | 69 | 未披露 | 未持股 | 2025-07-25 |
| Alexander Pickett | 男 | Chief Executive Officer and Director | 37 | 17.55万美元 | 未持股 | 2025-07-25 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Andrea E. Park | 女 | Chief Financial Officer | 53 | 30.56万美元 | 未持股 | 2025-07-25 |
| Robert Kramer | 男 | Chief Scientific Officer | 73 | 11.93万美元 | 未持股 | 2025-07-25 |
| Alexander Pickett | 男 | Chief Executive Officer and Director | 37 | 17.55万美元 | 未持股 | 2025-07-25 |
| Andrea E. Park | 女 | Chief Financial Officer | 53 | 未披露 | 未持股 | 2025-07-25 |
董事简历
中英对照 | 中文 | 英文- Gregory H. Bailey
-
Gregory H. Bailey，是医学博士。担任Medivation, Inc.的董事会成员（2005年以来）。目前担任Medivation, Inc.薪酬委员会和审计委员会的成员。2007年1月以来，一直担任Palantir Group公司（生物技术商业银行）的管理合伙人。从2006年4月到2008年12月，曾任职Opexa Therapeutics公司（Opexa，上市细胞疗法公司）的董事会。从2004年5月到2007年1月，曾担任MDB Capital Group公司（一个投资银行公司）的董事总经理。此前，曾担任 Participating Capital公司（投资银行公司）的生命科学分析师（1995年以来）。持有the University of Western Ontario的医学博士学位。
Gregory H. Bailey,joined Agex Therapeutics, Inc. Board of Directors in August 2018 and served as the Chairman of Agex Therapeutics, Inc. Board of Directors from October 2018 until May 2022. Dr. Bailey is currently Executive Chairman of Juvenescence Limited. From October 2017 until January 2023 Dr. Bailey served as the Chief Executive Officer of Juvenescence Limited, a privately held company focused on the development of therapies for ageing and age-related diseases. Dr. Bailey is also a director of Manx Financial Group, plc, BioHaven Inc, SalvaRx Inc and Portage Biotech. Dr. Bailey has founded and served as a director of a number of private and public companies and previously served as a managing partner of Palantir Group, Inc., a merchant bank involved in a number of biotech company startups and financings. Dr. Bailey practiced emergency medicine for ten years before entering finance. Dr. Bailey received his M.D. from the University of Western Ontario. - Gregory H. Bailey，是医学博士。担任Medivation, Inc.的董事会成员（2005年以来）。目前担任Medivation, Inc.薪酬委员会和审计委员会的成员。2007年1月以来，一直担任Palantir Group公司（生物技术商业银行）的管理合伙人。从2006年4月到2008年12月，曾任职Opexa Therapeutics公司（Opexa，上市细胞疗法公司）的董事会。从2004年5月到2007年1月，曾担任MDB Capital Group公司（一个投资银行公司）的董事总经理。此前，曾担任 Participating Capital公司（投资银行公司）的生命科学分析师（1995年以来）。持有the University of Western Ontario的医学博士学位。
- Gregory H. Bailey,joined Agex Therapeutics, Inc. Board of Directors in August 2018 and served as the Chairman of Agex Therapeutics, Inc. Board of Directors from October 2018 until May 2022. Dr. Bailey is currently Executive Chairman of Juvenescence Limited. From October 2017 until January 2023 Dr. Bailey served as the Chief Executive Officer of Juvenescence Limited, a privately held company focused on the development of therapies for ageing and age-related diseases. Dr. Bailey is also a director of Manx Financial Group, plc, BioHaven Inc, SalvaRx Inc and Portage Biotech. Dr. Bailey has founded and served as a director of a number of private and public companies and previously served as a managing partner of Palantir Group, Inc., a merchant bank involved in a number of biotech company startups and financings. Dr. Bailey practiced emergency medicine for ten years before entering finance. Dr. Bailey received his M.D. from the University of Western Ontario.
- Steven Mintz
-
Steven Mintz C.A.1989年毕业于多伦多大学，1989年至1992年进入公共会计专业，在一家大型会计师事务所工作。他于1992年6月获得了C.A.称号。1992年6月，他受雇于一家精品破产和破产公司，直到1997年1月。他于1995年获得破产许可的受托人。自1997年1月以来，他一直是一名自雇金融顾问，服务于私人和公司，以及各种行业的上市公司，包括采矿，石油和天然气，房地产和投资策略。他目前是St.Germain Capital Corp.（一家私人咨询和投资公司）的总裁。他也是家庭投资和发展公司Minkids Group的负责人和首席财务官。Steven自2009年12月起担任Pool Safe，Inc.的董事，Everton Resources，Inc.（自2023年5月起）IM Cannabis（自2018年4月起原Navasota Resources）。
Steven Mintz,joined Board of Directors during April 2016. Mr. Mintz has been a self-employed financial consultant since 1998, serving both private individuals and companies, as well as public companies in a variety of industries including mining, oil and gas, real estate, and investment strategies. He is currently President of St. Germain Capital Corp., a private consulting and investment firm. He is also a principal and CFO of the Minkids Group, a family investment and development company. Mr. Mintz is currently a director of Pool Safe, Inc. since December 2009. Mr. Mintz previously served as a director of Everton Resources, Inc. from May 2023 until September 2020, IM Cannabis (formerly Navasota Resources) from April 2018 until February 2021, and Serina Therapeutics, Inc. (NYSE American: SER, formerly AgeX Therapeutics, Inc.) from March 2024 until January 2025. Mr. Mintz graduated from the University of Toronto in 1989 and obtained his C.A. designation in June of 1992. - Steven Mintz C.A.1989年毕业于多伦多大学，1989年至1992年进入公共会计专业，在一家大型会计师事务所工作。他于1992年6月获得了C.A.称号。1992年6月，他受雇于一家精品破产和破产公司，直到1997年1月。他于1995年获得破产许可的受托人。自1997年1月以来，他一直是一名自雇金融顾问，服务于私人和公司，以及各种行业的上市公司，包括采矿，石油和天然气，房地产和投资策略。他目前是St.Germain Capital Corp.（一家私人咨询和投资公司）的总裁。他也是家庭投资和发展公司Minkids Group的负责人和首席财务官。Steven自2009年12月起担任Pool Safe，Inc.的董事，Everton Resources，Inc.（自2023年5月起）IM Cannabis（自2018年4月起原Navasota Resources）。
- Steven Mintz,joined Board of Directors during April 2016. Mr. Mintz has been a self-employed financial consultant since 1998, serving both private individuals and companies, as well as public companies in a variety of industries including mining, oil and gas, real estate, and investment strategies. He is currently President of St. Germain Capital Corp., a private consulting and investment firm. He is also a principal and CFO of the Minkids Group, a family investment and development company. Mr. Mintz is currently a director of Pool Safe, Inc. since December 2009. Mr. Mintz previously served as a director of Everton Resources, Inc. from May 2023 until September 2020, IM Cannabis (formerly Navasota Resources) from April 2018 until February 2021, and Serina Therapeutics, Inc. (NYSE American: SER, formerly AgeX Therapeutics, Inc.) from March 2024 until January 2025. Mr. Mintz graduated from the University of Toronto in 1989 and obtained his C.A. designation in June of 1992.
- Jean Christophe Renondin
-
Jean Christophe Renondin，医学博士，工商管理硕士，是一位经验丰富的医疗保健投资者，在全球医疗保健资产的融资和投资方面拥有20多年的经验。Renondin博士自2015年起担任阿曼主权基金OIa的高级医疗保健经理，负责医疗保健投资实践。他的主要职责是执行投资策略，并在北美、欧洲和亚洲发起和执行投资机会。最近的投资是Symetis和Cognate Bioservices。在加入OIA之前，Renondin博士是Bryan Garnier&Co.（一家泛欧洲投资银行）的董事总经理，负责医疗保健实践，领导欧洲医疗保健客户的ECM和私募交易。在此之前，Renondin博士是CDC Innovation的普通合伙人，投资于各种欧洲医疗保健资产。从1999年到2005年，Renondin博士担任Sofinov的副总裁，该公司是魁北克Caisse de Depot et Placement的子公司，领导医疗保健投资基金，并担任MDS Capital的董事总经理，该公司是加拿大领先的医疗保健投资公司之一。在1999年之前。他曾担任Servier Laboratories公司（位于爱尔兰和南非）的多种国际子公司的总经理，在那里他成功重组了几个部门。在Servier工作之前，Renondin博士在JP Morgan的医疗保健股票研究和公司财务部门的纽约办事处工作。Renondin博士目前担任Juvenescence的董事会成员，这是一家长寿生物技术公司，他此前曾担任Cognate Bioservices的董事会成员，也曾担任the VC Fund Innovation Development Oman的董事会和投资委员会成员。雷农丁博士于1991年在巴黎第五代笛卡尔大学获得医学博士学位，并在达特茅斯大学阿莫斯·塔克行政与金融学院获得工商管理硕士学位。
Jean Christophe Renondin,joined Board of Directors during April 2024. Since 2022, Dr. Renondin has served as Managing Partner at Vesalius Biocapital IV, a European life-sciences venture capital firm. From 2015 to 2022, Dr. Renondin served as Senior Healthcare Manager at the Sovereign Fund of Oman where he implemented investment strategy and pursued investment opportunities in North America, Europe and Asia. Dr. Renondin has served in management roles at a number of healthcare and investment firms, including serving for five years as managing director of Bryan Garnier & Co. Dr. Renondin served as a director of Cognate Bioservices Limited, a company in the business of contract development and manufacturing, specializing in cell and cell-mediated gene therapy products, which is now owned by Charles River Laboratories International and as a director of Juvenescence Limited from March 2020 until June 2023, and AgeX Therapeutics, Inc. from August 2023 until March 2024. Dr. Renondin received an MBA degree from the Tuck School of Business at Dartmouth University in 1991 and an MD degree from Universite Paris Cite. - Jean Christophe Renondin，医学博士，工商管理硕士，是一位经验丰富的医疗保健投资者，在全球医疗保健资产的融资和投资方面拥有20多年的经验。Renondin博士自2015年起担任阿曼主权基金OIa的高级医疗保健经理，负责医疗保健投资实践。他的主要职责是执行投资策略，并在北美、欧洲和亚洲发起和执行投资机会。最近的投资是Symetis和Cognate Bioservices。在加入OIA之前，Renondin博士是Bryan Garnier&Co.（一家泛欧洲投资银行）的董事总经理，负责医疗保健实践，领导欧洲医疗保健客户的ECM和私募交易。在此之前，Renondin博士是CDC Innovation的普通合伙人，投资于各种欧洲医疗保健资产。从1999年到2005年，Renondin博士担任Sofinov的副总裁，该公司是魁北克Caisse de Depot et Placement的子公司，领导医疗保健投资基金，并担任MDS Capital的董事总经理，该公司是加拿大领先的医疗保健投资公司之一。在1999年之前。他曾担任Servier Laboratories公司（位于爱尔兰和南非）的多种国际子公司的总经理，在那里他成功重组了几个部门。在Servier工作之前，Renondin博士在JP Morgan的医疗保健股票研究和公司财务部门的纽约办事处工作。Renondin博士目前担任Juvenescence的董事会成员，这是一家长寿生物技术公司，他此前曾担任Cognate Bioservices的董事会成员，也曾担任the VC Fund Innovation Development Oman的董事会和投资委员会成员。雷农丁博士于1991年在巴黎第五代笛卡尔大学获得医学博士学位，并在达特茅斯大学阿莫斯·塔克行政与金融学院获得工商管理硕士学位。
- Jean Christophe Renondin,joined Board of Directors during April 2024. Since 2022, Dr. Renondin has served as Managing Partner at Vesalius Biocapital IV, a European life-sciences venture capital firm. From 2015 to 2022, Dr. Renondin served as Senior Healthcare Manager at the Sovereign Fund of Oman where he implemented investment strategy and pursued investment opportunities in North America, Europe and Asia. Dr. Renondin has served in management roles at a number of healthcare and investment firms, including serving for five years as managing director of Bryan Garnier & Co. Dr. Renondin served as a director of Cognate Bioservices Limited, a company in the business of contract development and manufacturing, specializing in cell and cell-mediated gene therapy products, which is now owned by Charles River Laboratories International and as a director of Juvenescence Limited from March 2020 until June 2023, and AgeX Therapeutics, Inc. from August 2023 until March 2024. Dr. Renondin received an MBA degree from the Tuck School of Business at Dartmouth University in 1991 and an MD degree from Universite Paris Cite.
- James Mellon
-
詹姆斯·梅隆是一位作家、企业家和投资者。他是Portage Biotech的创始人之一，并与人合著了五本书，这些书的目的都是为了找出导致投资机会的新兴主题趋势。他是Agronomics Limited（LSE：ANIC）的创始人和执行董事，该公司是细胞农业和培育肉类的投资工具。他对长寿研究特别感兴趣，目前是抗衰老生物制药公司Juvenescence的联合创始人和董事长。他还是Condor Gold plc的非执行董事、Manx Financial Group plc董事会执行主席、Bradda Head Lithium（LSE：BHL.L）的联合创始人和非执行董事。他还是Endurance RP的联合创始人和董事长。梅隆先生是Portage Biotech Inc.董事会提名委员会成员，吉姆在牛津大学学习哲学、政治和经济学。
James Mellon,joined Board of Directors in February 2022. Mr. Mellon previously served on Board of Directors from June 2013 and resigned August 2020 to pursue other activities. Mr. Mellon is an entrepreneur, investor, and author. He is the co-author of five books, all written with a view toward identifying emerging thematic trends leading to investment opportunities. Mr. Mellon is a co-founder of Portage Biotech and the founder and Executive Chair of Agronomics Limited (LSE:ANIC), an investment vehicle for cultivated meat. Mr. Mellon has a particular interest in longevity research and is currently the co-founder and Director of anti-aging biopharma company, Juvenescence Limited. He is also a non-executive Chair of Condor Gold plc (LSE:CNR), the Executive Chair of Manx Financial Group plc (LSE:MFX), co-founder and Director of Bradda Head Lithium Limited (LSE:BHL.L), and the non-executive Chairman of the Board of SalvaRx Group plc. He is also the co-founder and Chair of Regent Pacific Group Limited (XHKG:575). Mr. Mellon holds a Master's Degree in Philosophy, Politics and Economics from Oxford University. - 詹姆斯·梅隆是一位作家、企业家和投资者。他是Portage Biotech的创始人之一，并与人合著了五本书，这些书的目的都是为了找出导致投资机会的新兴主题趋势。他是Agronomics Limited（LSE：ANIC）的创始人和执行董事，该公司是细胞农业和培育肉类的投资工具。他对长寿研究特别感兴趣，目前是抗衰老生物制药公司Juvenescence的联合创始人和董事长。他还是Condor Gold plc的非执行董事、Manx Financial Group plc董事会执行主席、Bradda Head Lithium（LSE：BHL.L）的联合创始人和非执行董事。他还是Endurance RP的联合创始人和董事长。梅隆先生是Portage Biotech Inc.董事会提名委员会成员，吉姆在牛津大学学习哲学、政治和经济学。
- James Mellon,joined Board of Directors in February 2022. Mr. Mellon previously served on Board of Directors from June 2013 and resigned August 2020 to pursue other activities. Mr. Mellon is an entrepreneur, investor, and author. He is the co-author of five books, all written with a view toward identifying emerging thematic trends leading to investment opportunities. Mr. Mellon is a co-founder of Portage Biotech and the founder and Executive Chair of Agronomics Limited (LSE:ANIC), an investment vehicle for cultivated meat. Mr. Mellon has a particular interest in longevity research and is currently the co-founder and Director of anti-aging biopharma company, Juvenescence Limited. He is also a non-executive Chair of Condor Gold plc (LSE:CNR), the Executive Chair of Manx Financial Group plc (LSE:MFX), co-founder and Director of Bradda Head Lithium Limited (LSE:BHL.L), and the non-executive Chairman of the Board of SalvaRx Group plc. He is also the co-founder and Chair of Regent Pacific Group Limited (XHKG:575). Mr. Mellon holds a Master's Degree in Philosophy, Politics and Economics from Oxford University.
- Justin Stebbing
-
Justin Stebbing，是OncoGene的主编，也是美国临床研究协会的成员。Stebbing博士拥有被任命为英国政府首位由英国国家健康研究所（NIHR）资助的肿瘤学教授的独特荣誉。他发表了700多篇论文，在新冠疫情期间，他从人工智能开始的工作导致了FDA对baricitinib的EUA，现在这是一种完全批准的类风湿性关节炎治疗药物。Stebbing是Portage Biotech Inc.董事会审计委员会和提名委员会的成员。Stebbing将他的医学生涯与医疗保健投资相结合。他曾与Atticus Capital、Lansdowne和Vitruvian Partners合作，此前曾担任BB Healthcare Trust董事会主席。在约翰霍普金斯医院住院之前，Stebbing博士获得了牛津三一学院的医学学位。他曾在皇家马斯登和巴特学院接受培训，在发展的各个阶段，他一直是众多研究的首席研究员。他此前是英国首位NIHR研究转化肿瘤学教授，同时也是剑桥ARU的生物医学科学教授。
Justin Stebbing,joined Board of Directors during April 2024 and began serving as the Chairman of the Board of Directors since December 15, 2024. Dr. Stebbing is Editor-in-Chief of the Springer Nature cancer journal, Oncogene, and a member of the American Society for Clinical Investigation. Dr. Stebbing holds the distinct honor of being appointed the British government's first oncology professor funded by the National Institute for Health Research (NIHR). He has published over 700 papers, concentrating on translational science, and during the COVID-19 pandemic, his work, starting with artificial intelligence, led to an FDA EUA for baricitinib, now a fully approved COVID-19 treatment, on the background of its previous Portage Biotech Inc. e in rheumatoid arthritis. Dr. Stebbing has combined his medical career with healthcare investing. He has worked with Atticus Capital, Lansdowne, and Vitruvian Partners, and previously chaired the board of BB Healthcare Trust from 2016 to 2021. Dr. Stebbing also currently serves as a director of Etira Therapeutics (since 2023) and Graviton Biosciences BV (since 2024). Prior to a residency at The Johns Hopkins Hospital, Dr. Stebbing gained a medical degree (first class) from Trinity College, Oxford. He undertook his fellowship/training at the Royal Marsden and Barts, and he has been a principal investigator on numerous studies through all phases of development. He is also a Professor of Biomedical Sciences at ARU, Cambridge. - Justin Stebbing，是OncoGene的主编，也是美国临床研究协会的成员。Stebbing博士拥有被任命为英国政府首位由英国国家健康研究所（NIHR）资助的肿瘤学教授的独特荣誉。他发表了700多篇论文，在新冠疫情期间，他从人工智能开始的工作导致了FDA对baricitinib的EUA，现在这是一种完全批准的类风湿性关节炎治疗药物。Stebbing是Portage Biotech Inc.董事会审计委员会和提名委员会的成员。Stebbing将他的医学生涯与医疗保健投资相结合。他曾与Atticus Capital、Lansdowne和Vitruvian Partners合作，此前曾担任BB Healthcare Trust董事会主席。在约翰霍普金斯医院住院之前，Stebbing博士获得了牛津三一学院的医学学位。他曾在皇家马斯登和巴特学院接受培训，在发展的各个阶段，他一直是众多研究的首席研究员。他此前是英国首位NIHR研究转化肿瘤学教授，同时也是剑桥ARU的生物医学科学教授。
- Justin Stebbing,joined Board of Directors during April 2024 and began serving as the Chairman of the Board of Directors since December 15, 2024. Dr. Stebbing is Editor-in-Chief of the Springer Nature cancer journal, Oncogene, and a member of the American Society for Clinical Investigation. Dr. Stebbing holds the distinct honor of being appointed the British government's first oncology professor funded by the National Institute for Health Research (NIHR). He has published over 700 papers, concentrating on translational science, and during the COVID-19 pandemic, his work, starting with artificial intelligence, led to an FDA EUA for baricitinib, now a fully approved COVID-19 treatment, on the background of its previous Portage Biotech Inc. e in rheumatoid arthritis. Dr. Stebbing has combined his medical career with healthcare investing. He has worked with Atticus Capital, Lansdowne, and Vitruvian Partners, and previously chaired the board of BB Healthcare Trust from 2016 to 2021. Dr. Stebbing also currently serves as a director of Etira Therapeutics (since 2023) and Graviton Biosciences BV (since 2024). Prior to a residency at The Johns Hopkins Hospital, Dr. Stebbing gained a medical degree (first class) from Trinity College, Oxford. He undertook his fellowship/training at the Royal Marsden and Barts, and he has been a principal investigator on numerous studies through all phases of development. He is also a Professor of Biomedical Sciences at ARU, Cambridge.
- Gregory H. Bailey
-
Gregory H. Bailey,2013年6月加入董事会，担任董事会主席至2016年8月。2017年10月至2023年1月，贝利博士担任Juvenescence Limited的首席执行官，该公司是一家私营公司，专注于开发针对衰老和与年龄相关疾病的疗法。Bailey博士自2023年1月起担任Juvenescence Limited的执行主席，同时也是Manx Financial Group，plc、BioHaven Inc、SalvaRx Group plc.、Culminant Reinsurance、Chelsea Avondale和Serina Therapeutics，Inc（纽约证券交易所美国代码：SER，前身为AgeX Therapeutics，Inc.）的董事。Bailey博士是Portage Biotech的联合创始人，曾创立多家私营公司和其他上市公司并担任其董事，此前曾担任PalantirGroup，Inc.的管理合伙人，该公司是一家商业银行，参与了多家生物技术公司的初创公司和融资。贝利医生在进入金融之前从事了十年的急诊医学工作。贝利博士在西安大略大学获得医学博士学位。
Gregory H. Bailey,joined Board of Directors in June 2013 and served as the Chairman of Board of Directors until August 2016. From October 2017 until January 2023, Dr. Bailey served as the Chief Executive Officer of Juvenescence Limited, a privately held company focused on the development of therapies for ageing and age-related diseases. Dr. Bailey has served as Executive Chairman of Juvenescence Limited since January 2023 and is also a director of Manx Financial Group, plc, BioHaven Inc, SalvaRx Group plc., Culminant Reinsurance, Chelsea Avondale, and Serina Therapeutics, Inc (NYSE American: SER, formerly AgeX Therapeutics, Inc.). Dr. Bailey is a co-founder of Portage Biotech and has founded and served as a director of a number of private and other public companies and previously served as a managing partner of Palantir Group, Inc., a merchant bank involved in a number of biotech company startups and financings. Dr. Bailey practiced emergency medicine for ten years before entering finance. Dr. Bailey received his M.D. from the University of Western Ontario. - Gregory H. Bailey,2013年6月加入董事会，担任董事会主席至2016年8月。2017年10月至2023年1月，贝利博士担任Juvenescence Limited的首席执行官，该公司是一家私营公司，专注于开发针对衰老和与年龄相关疾病的疗法。Bailey博士自2023年1月起担任Juvenescence Limited的执行主席，同时也是Manx Financial Group，plc、BioHaven Inc、SalvaRx Group plc.、Culminant Reinsurance、Chelsea Avondale和Serina Therapeutics，Inc（纽约证券交易所美国代码：SER，前身为AgeX Therapeutics，Inc.）的董事。Bailey博士是Portage Biotech的联合创始人，曾创立多家私营公司和其他上市公司并担任其董事，此前曾担任PalantirGroup，Inc.的管理合伙人，该公司是一家商业银行，参与了多家生物技术公司的初创公司和融资。贝利医生在进入金融之前从事了十年的急诊医学工作。贝利博士在西安大略大学获得医学博士学位。
- Gregory H. Bailey,joined Board of Directors in June 2013 and served as the Chairman of Board of Directors until August 2016. From October 2017 until January 2023, Dr. Bailey served as the Chief Executive Officer of Juvenescence Limited, a privately held company focused on the development of therapies for ageing and age-related diseases. Dr. Bailey has served as Executive Chairman of Juvenescence Limited since January 2023 and is also a director of Manx Financial Group, plc, BioHaven Inc, SalvaRx Group plc., Culminant Reinsurance, Chelsea Avondale, and Serina Therapeutics, Inc (NYSE American: SER, formerly AgeX Therapeutics, Inc.). Dr. Bailey is a co-founder of Portage Biotech and has founded and served as a director of a number of private and other public companies and previously served as a managing partner of Palantir Group, Inc., a merchant bank involved in a number of biotech company startups and financings. Dr. Bailey practiced emergency medicine for ten years before entering finance. Dr. Bailey received his M.D. from the University of Western Ontario.
- Alexander Pickett
-
Alexander Pickett，于2024年12月15日根据顾问协议加入董事会并被任命为首席执行官。皮克特先生还是Juvenescence的董事总经理，负责监督新的入职机会。Pickett先生还担任Morphoceuticals，Inc.的董事，该公司是一家专注于理解组织级计算和生物电在健康中的作用的Juvenescence投资组合公司。自2014年以来，Pickett先生在MediqVentures，Ltd.（一家多家族投资合伙企业和商业银行）与Juvenescence创始合伙人Gregory Bailey博士、Jim Mellon先生和Declan Doogan博士一起工作，在那里他审查了MediqVentures的新投资并支持Portage的现有投资，包括Portage Pharma Ltd.和Biohaven（NYSE：BHVN）。Pickett先生担任Causeway Therapeutics的董事，这是一家MediqVentures投资组合公司，专注于开发肌腱病的疗法。皮克特先生帮助找到了SalvaRX Limited，这是一家专注于癌症免疫治疗的投资公司，后来被并入了Portage Biotech。在加入MediqVentures之前，Pickett先生是Flatley Venture Capital的合伙人，该公司是John J Flatley公司旗下专注于囊性纤维化的投资部门，负责投资分析和科学尽职调查。皮克特先生与他人共同创立了Real Life Sciences，这是一家专注于基于软件的患者参与解决方案的初创公司，旨在改善临床试验的患者招募。Pickett先生拥有哈佛大学分子和细胞生物学学士学位。
Alexander Pickett,joined Board of Directors and was appointed as Chief Executive Officer under a consultancy agreement on December 15, 2024. Mr. Pickett is also the Managing Director at Juvenescence, where he oversees new opportunity onboarding. Mr. Pickett also serves as a Director of Morphoceuticals, Inc. a Juvenescence portfolio company focused on understanding the role of tissue-level computation and bioelectricity in health. Since 2014, Mr. Pickett has worked with Juvenescence founding partners Dr. Gregory Bailey, Mr. Jim Mellon, and Dr. Declan Doogan at Mediqventures, Ltd., a multi-family investment partnership and merchant bank, where he where he reviewed new investments for Mediqventures and supported existing investments at Portage, including Portage Pharma Ltd. and Biohaven (NYSE:BHVN). Mr. Pickett serves as a Director for Causeway Therapeutics, a Mediqventures portfolio company focused on the development of therapies for tendinopathy. Mr. Pickett helped find SalvaRx Limited, a cancer immunotherapy-focused investment company that was later merged into Portage Biotech. Prior to joining Mediqventures, Mr. Pickett was an associate at Flatley Venture Capital, a cystic fibrosis-focused investment arm of the John J Flatley Company, where he was responsible for investment analysis and scientific due diligence. Mr. Pickett co-founded Real Life Sciences, a start-up focused on software-based patient-engagement solutions to improve patient recruitment to clinical trials. Mr. Pickett has a BA in Molecular and Cellular Biology from Harvard College. - Alexander Pickett，于2024年12月15日根据顾问协议加入董事会并被任命为首席执行官。皮克特先生还是Juvenescence的董事总经理，负责监督新的入职机会。Pickett先生还担任Morphoceuticals，Inc.的董事，该公司是一家专注于理解组织级计算和生物电在健康中的作用的Juvenescence投资组合公司。自2014年以来，Pickett先生在MediqVentures，Ltd.（一家多家族投资合伙企业和商业银行）与Juvenescence创始合伙人Gregory Bailey博士、Jim Mellon先生和Declan Doogan博士一起工作，在那里他审查了MediqVentures的新投资并支持Portage的现有投资，包括Portage Pharma Ltd.和Biohaven（NYSE：BHVN）。Pickett先生担任Causeway Therapeutics的董事，这是一家MediqVentures投资组合公司，专注于开发肌腱病的疗法。皮克特先生帮助找到了SalvaRX Limited，这是一家专注于癌症免疫治疗的投资公司，后来被并入了Portage Biotech。在加入MediqVentures之前，Pickett先生是Flatley Venture Capital的合伙人，该公司是John J Flatley公司旗下专注于囊性纤维化的投资部门，负责投资分析和科学尽职调查。皮克特先生与他人共同创立了Real Life Sciences，这是一家专注于基于软件的患者参与解决方案的初创公司，旨在改善临床试验的患者招募。Pickett先生拥有哈佛大学分子和细胞生物学学士学位。
- Alexander Pickett,joined Board of Directors and was appointed as Chief Executive Officer under a consultancy agreement on December 15, 2024. Mr. Pickett is also the Managing Director at Juvenescence, where he oversees new opportunity onboarding. Mr. Pickett also serves as a Director of Morphoceuticals, Inc. a Juvenescence portfolio company focused on understanding the role of tissue-level computation and bioelectricity in health. Since 2014, Mr. Pickett has worked with Juvenescence founding partners Dr. Gregory Bailey, Mr. Jim Mellon, and Dr. Declan Doogan at Mediqventures, Ltd., a multi-family investment partnership and merchant bank, where he where he reviewed new investments for Mediqventures and supported existing investments at Portage, including Portage Pharma Ltd. and Biohaven (NYSE:BHVN). Mr. Pickett serves as a Director for Causeway Therapeutics, a Mediqventures portfolio company focused on the development of therapies for tendinopathy. Mr. Pickett helped find SalvaRx Limited, a cancer immunotherapy-focused investment company that was later merged into Portage Biotech. Prior to joining Mediqventures, Mr. Pickett was an associate at Flatley Venture Capital, a cystic fibrosis-focused investment arm of the John J Flatley Company, where he was responsible for investment analysis and scientific due diligence. Mr. Pickett co-founded Real Life Sciences, a start-up focused on software-based patient-engagement solutions to improve patient recruitment to clinical trials. Mr. Pickett has a BA in Molecular and Cellular Biology from Harvard College.
高管简历
中英对照 | 中文 | 英文- Andrea E. Park
Andrea E.Park于2020年5月被任命为AgeXTherapeutics，Inc.首席财务官。Park女士自2019年10月起担任Agex&8217；的财务副总裁兼财务总监。Park女士的职业生涯跨越了超过24年的公共会计和财务经验。在加入Agex之前，Park女士于2016年6月至2019年9月担任Lineage CellTherapeutics，Inc.（前身为BioTime，Inc.）的财务副总裁兼财务总监，并于2005年2月至2016年6月担任公司财务总监。在Eague任职期间，Park女士直接参与了公开分拆的会计和财务报告，并最终参与了其当时的三家子公司（包括海星生物治疗公司，Oncocyte Corporate和Agex）的合并。职业生涯早期，她曾任职Deloitte公司，从事审计和保证实践。Park女士拥有加州大学圣巴巴拉分校（University of California，Santa Barbara）的商业经济学学士学位，专注于会计。
Andrea E. Park,was appointed as Chief Financial Officer of AgeX Therapeutics, Inc. in May 2020. Ms. Park served as AgeX's Vice President of Finance and Controller since October 2019. Ms. Park's career spans over 24 years of public accounting and finance experience. Before joining AgeX, Ms. Park served as Vice President of Finance and Controller from June 2016 to September 2019 and as Corporate Controller from August 2009 to June 2016 for Lineage Cell Therapeutics, Inc. (formerly BioTime, Inc.). While at Lineage, Ms. Park was directly involved in the accounting and financial reporting of the public spin off and eventually the deconsolidation of three of its then subsidiaries including Asterias Biotherapeutics, Inc., Oncocyte Corporation and AgeX. Earlier in her career she worked in the audit and assurance practice at Deloitte. Ms. Park has a B.A. in Business Economics with Concentration in Accounting from the University of California, Santa Barbara.- Andrea E.Park于2020年5月被任命为AgeXTherapeutics，Inc.首席财务官。Park女士自2019年10月起担任Agex&8217；的财务副总裁兼财务总监。Park女士的职业生涯跨越了超过24年的公共会计和财务经验。在加入Agex之前，Park女士于2016年6月至2019年9月担任Lineage CellTherapeutics，Inc.（前身为BioTime，Inc.）的财务副总裁兼财务总监，并于2005年2月至2016年6月担任公司财务总监。在Eague任职期间，Park女士直接参与了公开分拆的会计和财务报告，并最终参与了其当时的三家子公司（包括海星生物治疗公司，Oncocyte Corporate和Agex）的合并。职业生涯早期，她曾任职Deloitte公司，从事审计和保证实践。Park女士拥有加州大学圣巴巴拉分校（University of California，Santa Barbara）的商业经济学学士学位，专注于会计。
- Andrea E. Park,was appointed as Chief Financial Officer of AgeX Therapeutics, Inc. in May 2020. Ms. Park served as AgeX's Vice President of Finance and Controller since October 2019. Ms. Park's career spans over 24 years of public accounting and finance experience. Before joining AgeX, Ms. Park served as Vice President of Finance and Controller from June 2016 to September 2019 and as Corporate Controller from August 2009 to June 2016 for Lineage Cell Therapeutics, Inc. (formerly BioTime, Inc.). While at Lineage, Ms. Park was directly involved in the accounting and financial reporting of the public spin off and eventually the deconsolidation of three of its then subsidiaries including Asterias Biotherapeutics, Inc., Oncocyte Corporation and AgeX. Earlier in her career she worked in the audit and assurance practice at Deloitte. Ms. Park has a B.A. in Business Economics with Concentration in Accounting from the University of California, Santa Barbara.
- Robert Kramer
Robert Kramer在制药行业拥有24年的经验，是Bristol Myers Squibb和Janssen Pharmaceuticals（强生公司Group of Companies的一部分）肿瘤发现研究的前任主管。他负责将35种药物从最初的发现转移到临床。Robert支持Bristol Myers Squibb的免疫疗法，该公司在2009年牵头收购了Medarex，Inc.及其免疫疗法投资组合，其中包括ipilimumab和nivolumab。他在佛蒙特大学获得药理学博士学位，并在美国国家癌症研究所从事博士后研究。罗伯特还曾在哈佛医学院担任助理教授。
Robert Kramer,has served as Chief Scientific Officer since January 2019. Dr. Kramer has over 33 years of experience in the pharmaceutical industry and is the former Head of Oncology Discovery Research at both Bristol Myers Squibb and Janssen Pharmaceuticals, part of the Johnson & Johnson group of companies. He has been responsible for enabling the transition of 35 drugs from initial discovery into the clinic. Robert championed immunotherapy at Bristol Myers Squibb, which led, in 2009 to the acquisition of Medarex, Inc. and its portfolio of immune therapeutics that included Ipilimumab and Nivolumab. He received his PhD in pharmacology from the University of Vermont and undertook his post doctorate studies at the U.S. National Cancer Institute. Robert has also held an Assistant Professorship at the Harvard Medical School.- Robert Kramer在制药行业拥有24年的经验，是Bristol Myers Squibb和Janssen Pharmaceuticals（强生公司Group of Companies的一部分）肿瘤发现研究的前任主管。他负责将35种药物从最初的发现转移到临床。Robert支持Bristol Myers Squibb的免疫疗法，该公司在2009年牵头收购了Medarex，Inc.及其免疫疗法投资组合，其中包括ipilimumab和nivolumab。他在佛蒙特大学获得药理学博士学位，并在美国国家癌症研究所从事博士后研究。罗伯特还曾在哈佛医学院担任助理教授。
- Robert Kramer,has served as Chief Scientific Officer since January 2019. Dr. Kramer has over 33 years of experience in the pharmaceutical industry and is the former Head of Oncology Discovery Research at both Bristol Myers Squibb and Janssen Pharmaceuticals, part of the Johnson & Johnson group of companies. He has been responsible for enabling the transition of 35 drugs from initial discovery into the clinic. Robert championed immunotherapy at Bristol Myers Squibb, which led, in 2009 to the acquisition of Medarex, Inc. and its portfolio of immune therapeutics that included Ipilimumab and Nivolumab. He received his PhD in pharmacology from the University of Vermont and undertook his post doctorate studies at the U.S. National Cancer Institute. Robert has also held an Assistant Professorship at the Harvard Medical School.
- Alexander Pickett
Alexander Pickett，于2024年12月15日根据顾问协议加入董事会并被任命为首席执行官。皮克特先生还是Juvenescence的董事总经理，负责监督新的入职机会。Pickett先生还担任Morphoceuticals，Inc.的董事，该公司是一家专注于理解组织级计算和生物电在健康中的作用的Juvenescence投资组合公司。自2014年以来，Pickett先生在MediqVentures，Ltd.（一家多家族投资合伙企业和商业银行）与Juvenescence创始合伙人Gregory Bailey博士、Jim Mellon先生和Declan Doogan博士一起工作，在那里他审查了MediqVentures的新投资并支持Portage的现有投资，包括Portage Pharma Ltd.和Biohaven（NYSE：BHVN）。Pickett先生担任Causeway Therapeutics的董事，这是一家MediqVentures投资组合公司，专注于开发肌腱病的疗法。皮克特先生帮助找到了SalvaRX Limited，这是一家专注于癌症免疫治疗的投资公司，后来被并入了Portage Biotech。在加入MediqVentures之前，Pickett先生是Flatley Venture Capital的合伙人，该公司是John J Flatley公司旗下专注于囊性纤维化的投资部门，负责投资分析和科学尽职调查。皮克特先生与他人共同创立了Real Life Sciences，这是一家专注于基于软件的患者参与解决方案的初创公司，旨在改善临床试验的患者招募。Pickett先生拥有哈佛大学分子和细胞生物学学士学位。
Alexander Pickett,joined Board of Directors and was appointed as Chief Executive Officer under a consultancy agreement on December 15, 2024. Mr. Pickett is also the Managing Director at Juvenescence, where he oversees new opportunity onboarding. Mr. Pickett also serves as a Director of Morphoceuticals, Inc. a Juvenescence portfolio company focused on understanding the role of tissue-level computation and bioelectricity in health. Since 2014, Mr. Pickett has worked with Juvenescence founding partners Dr. Gregory Bailey, Mr. Jim Mellon, and Dr. Declan Doogan at Mediqventures, Ltd., a multi-family investment partnership and merchant bank, where he where he reviewed new investments for Mediqventures and supported existing investments at Portage, including Portage Pharma Ltd. and Biohaven (NYSE:BHVN). Mr. Pickett serves as a Director for Causeway Therapeutics, a Mediqventures portfolio company focused on the development of therapies for tendinopathy. Mr. Pickett helped find SalvaRx Limited, a cancer immunotherapy-focused investment company that was later merged into Portage Biotech. Prior to joining Mediqventures, Mr. Pickett was an associate at Flatley Venture Capital, a cystic fibrosis-focused investment arm of the John J Flatley Company, where he was responsible for investment analysis and scientific due diligence. Mr. Pickett co-founded Real Life Sciences, a start-up focused on software-based patient-engagement solutions to improve patient recruitment to clinical trials. Mr. Pickett has a BA in Molecular and Cellular Biology from Harvard College.- Alexander Pickett，于2024年12月15日根据顾问协议加入董事会并被任命为首席执行官。皮克特先生还是Juvenescence的董事总经理，负责监督新的入职机会。Pickett先生还担任Morphoceuticals，Inc.的董事，该公司是一家专注于理解组织级计算和生物电在健康中的作用的Juvenescence投资组合公司。自2014年以来，Pickett先生在MediqVentures，Ltd.（一家多家族投资合伙企业和商业银行）与Juvenescence创始合伙人Gregory Bailey博士、Jim Mellon先生和Declan Doogan博士一起工作，在那里他审查了MediqVentures的新投资并支持Portage的现有投资，包括Portage Pharma Ltd.和Biohaven（NYSE：BHVN）。Pickett先生担任Causeway Therapeutics的董事，这是一家MediqVentures投资组合公司，专注于开发肌腱病的疗法。皮克特先生帮助找到了SalvaRX Limited，这是一家专注于癌症免疫治疗的投资公司，后来被并入了Portage Biotech。在加入MediqVentures之前，Pickett先生是Flatley Venture Capital的合伙人，该公司是John J Flatley公司旗下专注于囊性纤维化的投资部门，负责投资分析和科学尽职调查。皮克特先生与他人共同创立了Real Life Sciences，这是一家专注于基于软件的患者参与解决方案的初创公司，旨在改善临床试验的患者招募。Pickett先生拥有哈佛大学分子和细胞生物学学士学位。
- Alexander Pickett,joined Board of Directors and was appointed as Chief Executive Officer under a consultancy agreement on December 15, 2024. Mr. Pickett is also the Managing Director at Juvenescence, where he oversees new opportunity onboarding. Mr. Pickett also serves as a Director of Morphoceuticals, Inc. a Juvenescence portfolio company focused on understanding the role of tissue-level computation and bioelectricity in health. Since 2014, Mr. Pickett has worked with Juvenescence founding partners Dr. Gregory Bailey, Mr. Jim Mellon, and Dr. Declan Doogan at Mediqventures, Ltd., a multi-family investment partnership and merchant bank, where he where he reviewed new investments for Mediqventures and supported existing investments at Portage, including Portage Pharma Ltd. and Biohaven (NYSE:BHVN). Mr. Pickett serves as a Director for Causeway Therapeutics, a Mediqventures portfolio company focused on the development of therapies for tendinopathy. Mr. Pickett helped find SalvaRx Limited, a cancer immunotherapy-focused investment company that was later merged into Portage Biotech. Prior to joining Mediqventures, Mr. Pickett was an associate at Flatley Venture Capital, a cystic fibrosis-focused investment arm of the John J Flatley Company, where he was responsible for investment analysis and scientific due diligence. Mr. Pickett co-founded Real Life Sciences, a start-up focused on software-based patient-engagement solutions to improve patient recruitment to clinical trials. Mr. Pickett has a BA in Molecular and Cellular Biology from Harvard College.
- Andrea E. Park
Andrea E. Park，于2024年9月30日被任命为首席财务官。Park女士此前曾在Serina Therapeutics，Inc.（NYSE American：SER）担任临时首席财务官和首席会计官，直至2024年8月15日，此前该公司于2024年3月完成了与AgeX Therapeutics，Inc.（AGEX）的反向收购。在合并之前，Park女士自2020年5月起担任AgeX的首席财务官，并自2019年10月起担任财务副总裁兼财务总监。朴女士的职业生涯跨越了超过25年的公共会计和财务经验。在加入AGEX之前，Park女士于2016年6月至2019年9月担任财务副总裁兼财务总监，并于2009年8月至2016年6月担任Lineage Cell Therapeutics, Inc.（纽约证券交易所美国代码：LCTX，前身为BioTime，Inc.）的公司财务总监。在她职业生涯的早期，她曾在德勤从事审计和鉴证业务。Park女士是加利福尼亚州的一名注册会计师，拥有加州大学圣巴巴拉分校会计学专业的商业经济学学士学位。
Andrea E. Park,was appointed as Chief Financial Officer on September 30, 2024. Ms. Park previously served as Interim Chief Financial Officer and Chief Accounting Officer of Serina Therapeutics, Inc. (NYSE American: SER) through August 15, 2024, following the consummation of the reverse merger with AgeX Therapeutics, Inc. (AgeX) in March 2024. Prior to the merger, Ms. Park served as Chief Financial Officer for AgeX since May 2020 and as Vice President of Finance and Controller from October 2019. Ms. Park's career spans over 25 years of public accounting and finance experience. Before joining AgeX, Ms. Park served as Vice President of Finance and Controller from June 2016 to September 2019 and as Corporate Controller from August 2009 to June 2016 for Lineage Cell Therapeutics, Inc. (NYSE American: LCTX, formerly BioTime, Inc.). Earlier in her career, she worked in the audit and assurance practice at Deloitte. Ms. Park is a certified public accountant in the State of California and has a B.A. in Business Economics with Concentration in Accounting from the University of California, Santa Barbara.- Andrea E. Park，于2024年9月30日被任命为首席财务官。Park女士此前曾在Serina Therapeutics，Inc.（NYSE American：SER）担任临时首席财务官和首席会计官，直至2024年8月15日，此前该公司于2024年3月完成了与AgeX Therapeutics，Inc.（AGEX）的反向收购。在合并之前，Park女士自2020年5月起担任AgeX的首席财务官，并自2019年10月起担任财务副总裁兼财务总监。朴女士的职业生涯跨越了超过25年的公共会计和财务经验。在加入AGEX之前，Park女士于2016年6月至2019年9月担任财务副总裁兼财务总监，并于2009年8月至2016年6月担任Lineage Cell Therapeutics, Inc.（纽约证券交易所美国代码：LCTX，前身为BioTime，Inc.）的公司财务总监。在她职业生涯的早期，她曾在德勤从事审计和鉴证业务。Park女士是加利福尼亚州的一名注册会计师，拥有加州大学圣巴巴拉分校会计学专业的商业经济学学士学位。
- Andrea E. Park,was appointed as Chief Financial Officer on September 30, 2024. Ms. Park previously served as Interim Chief Financial Officer and Chief Accounting Officer of Serina Therapeutics, Inc. (NYSE American: SER) through August 15, 2024, following the consummation of the reverse merger with AgeX Therapeutics, Inc. (AgeX) in March 2024. Prior to the merger, Ms. Park served as Chief Financial Officer for AgeX since May 2020 and as Vice President of Finance and Controller from October 2019. Ms. Park's career spans over 25 years of public accounting and finance experience. Before joining AgeX, Ms. Park served as Vice President of Finance and Controller from June 2016 to September 2019 and as Corporate Controller from August 2009 to June 2016 for Lineage Cell Therapeutics, Inc. (NYSE American: LCTX, formerly BioTime, Inc.). Earlier in her career, she worked in the audit and assurance practice at Deloitte. Ms. Park is a certified public accountant in the State of California and has a B.A. in Business Economics with Concentration in Accounting from the University of California, Santa Barbara.